Interleukin 3 News and Research

RSS

Induction of potent antitumor immunity by intratumoral injection of IL-23 transduced dendritic cells

One therapy for treating brain tumors alerts the immune system to the presence of foreign material. A second therapy enhances the first and prolongs the immune system's response.

4 Sep 2006

Scientists create tumour zapping T cells which knock out cancer

Scientists in the United States have genetically engineered normal immune cells to become specialized fighters and used them to attack cancerous tumours.

31 Aug 2006

Trying to improve on the activity of Interferon-Alpha in metastatic renal cell carcinoma

Interferon-alpha (IFN) has been a mainstay in the systemic treatment of metastatic renal cell carcinoma (RCC) for decades, with response rates ranging from 3-15%.

16 Aug 2006

Drug trial fiasco induced immune system overload in patients

The doctors who treated six British men in a trial of a drug in March which went horribly wrong, say they believe the men suffered an immune system overreaction known as a cytokine storm.

15 Aug 2006

Interleukin 21 may enhance the effectiveness of Herceptin

Preliminary research suggests that a drug that targets a particular type of breast cancer might be more effective if patients are also given a substance made by the body that stimulates certain immune cells.

6 Aug 2006

A tipple a day keeps heart attacks away

Researchers say that seniors who have a drink each day may live longer and suffer fewer heart problems than teetotalers do, but they are not sure why.

27 Jul 2006

Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain

Chronic widespread pain, a common medical condition, can be difficult to treat and is often associated with fatigue, poor sleep and depression.

26 Jul 2006

Mechanism linking alcohol to reduced risk of cardiovascular disease may be related to inflammation

Older adults who consume one to seven alcoholic beverages a week may live longer and have a reduced risk for cardiac events than those who do not drink - an association that appears independent of the anti-inflammatory effects of alcohol.

25 Jul 2006

Nexavar approved in Europe for treatment of advanced kidney cancer

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc have announced that the European Commission has granted marketing authorization to Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma.

24 Jul 2006

Scientists find a cytokine against auto-immune hepatitis

There are about 400 million patients of hepatitis in the world. Some of them are suffering from autoimmune hepatitis, a disease in which the body's immune system attacks liver cells.

5 Jul 2006

Japanese researchers using PET imaging detect the beginnings of atherosclerosis

Using positron emission tomography (PET), the medical isotope 15O-water and cold pressor tests, Japanese researchers were able to detect the beginnings of atherosclerosis - before the disease became clinically evident.

9 Jun 2006

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006

Circulating tumor cells in the bone marrow of patients with metastatic renal cell carcinoma may be prognostic of outcome

Circulating tumor cells in the blood and bone marrow have been examined in a variety of malignancies, including colorectal, breast, and head & neck cancers, to determine their prognostic significance.

8 May 2006

Therapeutic gene suspected to cause cancer

One of the few gene therapy studies that had ever been successful was terminated in 2003, because several of the treated children had developed leukemia.

3 May 2006

Inflammation markers identify fatigue in breast cancer survivors

Researchers at the University of California, Los Angeles have defined conditions associated with disabling fatigue that persists for years in almost a third of breast cancer survivors, according to a study in the May 1 issue of Clinical Cancer Research.

3 May 2006

New insights into how anti-rejection drug daclizumab (Zenapax) helps MS patients

A research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into the role of the MS drug daclizumab (Zenapax) in the Proceedings of the National Academy of Sciences.

11 Apr 2006

Role of hepatic STAT3 in brain-insulin action on hepatic glucose production

New research in Cell Metabolism identifies a key player in the body's ability to respond to insulin action in the brain by ratcheting down the export of blood sugar from the liver.

6 Apr 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

Immune system protein LL-37 critical in controlling replication of vaccinia virus

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have identified a defect in the immune response of people with the skin condition atopic dermatitis that puts them at risk of developing serious complications following smallpox vaccination.

23 Mar 2006

Potential therapeutic targets against serious side effects of smallpox vaccine

Smallpox is considered a potential terrorist weapon, but millions of people in the United States are currently advised not to get a vaccine to the disease because they are susceptible to developing a severe adverse reaction.

23 Mar 2006